Kyoto University · 의학
다이스케 나카지마 교수의 연구실은 이식 가능한 폐를 확대하기 위한 혁신적 기술 개발에 주력하고 있습니다. 특히 고체기증자 폐(DCD 폐)과 감염된 기증자 폐를 대상으로 한 외과적 이식 전 폐 보존 기술인 고온에서의 폐 순환(Ex vivo lung perfusion, EVLP)과 단기 고온 보존(HMP) 기술을 핵심으로 연구를 진행하고 있습니다. 이는 폐 이식의 기증자 폐 활용도를 높이고, 이식 후 합병증을 줄이는 데 기여합니다.
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
Ex vivo lung perfusion (EVLP) is a platform to treat infected donor lungs with antibiotic therapy before lung transplantation. Human donor lungs that were rejected for transplantation because of clinical concern regarding infection were randomly assigned to two groups. In the antibiotic group (n = 8), lungs underwent EVLP for 12 h with high-dose antibiotics (ciprofloxacin 400 mg or azithromycin 500 mg, vancomycin 15 mg/kg, and meropenem 2 g). In the control group (n = 7), lungs underwent EVLP fo
Short-term HMP improved lung tissue energy levels that decreased during warm ischemia and ameliorated ischemia-reperfusion injury with decreased production of reactive oxygen species.
Living-donor lobar lung transplantation (LDLLT) has become an important life-saving option for patients with severe respiratory disorders, since it was developed by a group in the University of Southern California in 1993 and introduced in Japan in 1998 in order to address the current severe shortage of brain-dead donor organs. Although LDLLT candidates were basically limited to critically ill patients who would require hospitalization, the long-term use of steroids, and/or mechanical respirator
Short-term HMP could resuscitate ischemically damaged DCD lungs and ameliorate ischemia-reperfusion injury.
